This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


trusted source


Early research finds hope in stem cell therapy for perianal fistulas in patients with Crohn's disease

stem cell
Credit: CC0 Public Domain

A dissolvable plug delivered stem cell therapy with few side effects in patients with single tract perianal fistulas, Mayo Clinic researchers discovered. Perianal fistulas are painful tunnels between the intestine and the skin that often do not go away with standard medical or surgical care. People with Crohn's disease or other inflammatory bowel conditions are most at risk for this condition.

In a prospective, phase 1 clinical trial, researchers loaded stem cells from a patient's own fat tissue onto a bioabsorbable plug that was then surgically implanted to close the anal fistula tract. They followed the patients for one year and reported results of their early research in Diseases of the Colon & Rectum.

"In this early study, our team documented healing of single-tract fistulas," says Eric Dozois, M.D., a colorectal surgeon and first author on the study. "In my 20 years of clinical experience, our fistula research suggests we are getting closer to a care model."

As many as 26% of people with Crohn's disease will develop perianal fistulas. Most often, it starts with an infection within the anal gland and often progresses into an abscess that sometimes requires surgery. Left untreated, perianal fistulas leak fecal material and can lead to permanent colostomy and, in some cases, cancer. A colostomy is a surgical opening in the abdomen that bypasses the damaged colon to rid the body of solid waste. Perianal fistulas can cause quality-of-life challenges, such as the need to wear pads to protect clothing and prevent odor.

"Perianal fistulas are a complex medical condition that—even when repaired surgically—can recur, causing a lot of suffering for patients," says William Faubion Jr., M.D., a gastroenterologist and senior author on the study. "Our hope with this research is to advance a cell-based therapy toward daily clinical care that would be easy to implant in the operating room and offer a new option for patients with unmet needs."

The research

The research team extracted from adipose (fat) tissue of 20 patients with perianal fistulas who had not responded to standard medical or surgical treatment. Mesenchymal stem cells are adult stem cells with healing potential that have been well studied. After multiplying the in the lab, the team combined the cells with a plug created from a dissolvable material. They surgically implanted the plug to close the anal fistula tract, then monitored the patients seven times within 12 months, with a focus on investigating safety. They also studied whether the treatment intervention led to clinical healing that could be confirmed through deep tissue imaging.

Dr. Dozois's team documented complete healing of 14 patients at six months and 13 patients at one year. Three patients withdrew for various reasons during the course of the clinical trial.

Four participants reported side effects such as infections that required admission to the hospital or surgical draining of an abscess. Twelve participants experienced reactions considered to be minor, such as redness, fever or nausea.

Based on their findings, Dr. Dozois's team is recommending further study of the stem cell-coated plug with larger sample sizes and more types of fistulas. If all goes well, it could take two or three years before this procedure is approved for routine clinical care.

More information: Eric J. Dozois et al, Durable Response in Patients With Refractory Fistulizing Perianal Crohn's Disease Using Autologous Mesenchymal Stem Cells on a Dissolvable Matrix: Results from the Phase I Stem Cell on Matrix Plug Trial, Diseases of the Colon & Rectum (2022). DOI: 10.1097/DCR.0000000000002579

Provided by Mayo Clinic
Citation: Early research finds hope in stem cell therapy for perianal fistulas in patients with Crohn's disease (2023, March 2) retrieved 25 July 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Nanofiber-hydrogel loaded with stem cells shows success treating severe complication of Crohn's disease


Feedback to editors